Search

Your search keyword '"Aikata, Hiroshi"' showing total 1,388 results
Start Over Author "Aikata, Hiroshi"
1,388 results on '"Aikata, Hiroshi"'

1. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)

Author

Kobayashi, Kazufumi, Ogasawara, Sadahisa, Itobayashi, Ei, Okubo, Tomomi, Itokawa, Norio, Nakamura, Kazuyoshi, Moriguchi, Michihisa, Watanabe, Shunji, Ikeda, Masafumi, Kuroda, Hidekatsu, Kawaoka, Tomokazu, Hiraoka, Atsushi, Yasui, Yutaka, Kuzuya, Teiji, Sato, Rui, Kanzaki, Hiroaki, Koroki, Keisuke, Inoue, Masanori, Nakamura, Masato, Kiyono, Soichiro, Kanogawa, Naoya, Kondo, Takayuki, Nakamoto, Shingo, Ozawa, Yoshihito, Tsuchiya, Kaoru, Atsukawa, Masanori, Aikata, Hiroshi, Aramaki, Takeshi, Oka, Shiro, Morimoto, Naoki, Kurosaki, Masayuki, Itoh, Yoshito, Izumi, Namiki, and Kato, Naoya

Published
2024
Full Text
View/download PDF

2. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

Author

Murakami, Serami, Imamura, Michio, Uchida, Takuro, Suehiro, Yosuke, Namba, Maiko, Fujii, Yasutoshi, Uchikawa, Shinsuke, Teraoka, Yuji, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Miki, Daiki, Hayes, Nelson C., Tsuge, Masataka, Aikata, Hiroshi, Ohira, Masahiro, Ohdan, Hideki, and Oka, Shiro

Published
2023
Full Text
View/download PDF

3. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

Author

Yamauchi, Masami, Ono, Atsushi, Amioka, Kei, Fujii, Yasutoshi, Nakahara, Hikaru, Teraoka, Yuji, Uchikawa, Shinsuke, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Miki, Daiki, Kawaoka, Tomokazu, Tsuge, Masataka, Imamura, Michio, Hayes, C. Nelson, Ohishi, Waka, Kishi, Takeshi, Kimura, Mizuki, Suzuki, Natsumi, Arihiro, Koji, Aikata, Hiroshi, Chayama, Kazuaki, and Oka, Shiro

Published
2023
Full Text
View/download PDF

4. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study

Author

Johira, Yusuke, Nakahara, Takashi, Kinami, Takahiro, Yamasaki, Shintaro, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Hayes, C. Nelson, Tsuge, Masataka, Imamura, Michio, Aikata, Hiroshi, and Oka, Shiro

Published
2023
Full Text
View/download PDF

6. Targeting the liver clock improves fibrosis by restoring TGF-β signaling

Author

Crouchet, Emilie, Dachraoui, Mayssa, Jühling, Frank, Roehlen, Natascha, Oudot, Marine A., Durand, Sarah C., Ponsolles, Clara, Gadenne, Cloé, Meiss-Heydmann, Laura, Moehlin, Julien, Martin, Romain, Brignon, Nicolas, Del Zompo, Fabio, Teraoka, Yuji, Aikata, Hiroshi, Abe-Chayama, Hiromi, Chayama, Kazuaki, Saviano, Antonio, Heide, Danijela, Onea, Mihaela, Geyer, Lucas, Wolf, Thibaut, Felli, Emanuele, Pessaux, Patrick, Heikenwälder, Mathias, Chambon, Pierre, Schuster, Catherine, Lupberger, Joachim, Mukherji, Atish, and Baumert, Thomas F.

Published
2024
Full Text
View/download PDF

8. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Strasser, Simone, Thompson, Alexander, Roohullah, Aflah, Sievert, William, Andelkovic, Vladimir, Knox, Jennifer, Davies, Janine, Asselah, Jamil, Brahmania, Mayur, Majeed, Habeeb, Villanueva, Luis, Yanez Weber, Patricio, Garrido, Marcelo, Pizarro, Gonzalo Ignacio, Yanez, Nicolas, Xu, Ruocai, Ou, Shuangyan, Ren, Zhenggang, Pan, Hongming, Meng, Zhiqiang, Gu, Kangsheng, Chen, Xi, Zhang, Tao, Hao, Chunyi, Cao, Peiguo, Guo, Yabing, Qin, Shukui, Xiao, Juxiang, Fang, Weijia, Wang, Xin, Bai, Yuxian, Chen, Xiaoming, Yan, Dong, Zhao, Hong, Ying, Jieer, Bonilla, Carlos, Urrego, Olga, Zambrano, Angela, Lema, Mauricio, Restrepo Gutierrez, Juan Carlos, Cardona, Andres, Franco Millan, Sandra, Oscar, Madiedo, Ramos, Victor, Merle, Philippe, LeSourd, Samuel, Edeline, Julien, Bronowicki, Jean-Pierre, Bourliere, Marc, Cattan, Stephane, Bouattour, Mohamed, Mineur, Laurent, Regnault, Helene, Dauvois, Barbara, Schulze, Kornelius, Folprecht, Gunnar, Geier, Andreas, Waidmann, Oliver, Finkelmeier, Fabian, Venerito, Marino, Berres, Marie-Luise, Berg, Thomas, Lange, Christian, Schmidt, Hartmut, Waldschmidt, Dirk T, Bitzer, Michael, McDermott, Ray, Duffy, Austin, Masi, Gianluca, Zagonel, Vittorina, Tonini, Giuseppe, Piscaglia, Fabio, Gori, Stefania, Rizzo, Mimma, Biscaldi, Elisa, Foltran, Luisa, Cabibbo, Giuseppe, Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Numata, Kazushi, Marusawa, Hiroyuki, Kato, Naoya, Kurosaki, Masayuki, Morimoto, Manabu, Yamashita, Tatsuya, Koga, Hironori, Masaki, Tsutomu, Tateishi, Ryosuke, Inaba, Yoshitaka, Arakawa, Tomohiro, Suzuki, Yoshiyuki, Akua, Norio, Kobayashi, Masahiro, Hosaka, Tetsuya, Nakamuta, Makoto, Oza, Noriko, Kondo, Shunsuke, Furuse, Junji, Nagashima, Fumio, Kitano, Masayuki, Takaguchi, Koichi, Ryoo, Baek-Yeol, Lim, Ho Yeong, Kim, Jee Hyun, Kim, Tae-You, Kim, Han Sang, Hernandez Hernandez, Carlos, Motola Kuba, Daniel, Segura Gonzalez, Manuel, Cabrera Luviano, Jesus, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Silva-Bravo, Fernando, Gane, Edward, Stedman, Catherine, Kwiatkowski, Mariusz, Wyrwicz, Lucjan, Nowakowska-Zajdel, Ewa, Kraj, Leszek, Janczewska, Ewa, Surma-Wlodarczyk, Renata, Breder, Valeriy, Sekacheva, Marina, Orlova, Rashida, Vasilyev, Alexander, Zukov, Ruslan, Vladimirov, Vladimir, Minguez, Beatriz, Matilla Pena, Ana, Fernandez Castroagudin, Javier, Romero Gomez, Manuel, Luis Lledo, Jose, Rubin, Angel, Garcia Sanchez, Araceli, Calleja Panero, Jose, Yu, Ming-Chin, Shen, Ying-Chun, Huang, Yi-Hsiang, Jeng, Long-Bin, Chang, Ting-Tsung, Yang, Sheng-Shun, Chen, Shinn-Cherng, Dechaphunkul, Arunee, Tanwandee, Tawesak, Leerapun, Apinya, Seker, Mesut, Harputluoglu, Hakan, Cicin, Irfan, Oksuzoglu, Berna, Bilici, Mehmet, Sezgin Goksu, Sema, Artac, Mehmet, Cil, Timucin, Yalcin, Suayib, Meyer, Tim, Sarker, Debashis, Rao, Ankit, Palmer, Daniel, Evans, Jeff, Hubner, Richard, Finn, Richard, Ulahannan, Susanna, Zakari, Ahmed, Feun, Lynn, Al-Rajabi, Raed, Sung, Max, He, Aiwu, Kardosh, Adel, Goyal, Lipika, Li, Daneng, Choi, Minsig, Posada, Juan, Dodlapati, Jyothi, Shroff, Rachna, Agrawal, Saurabh, Gopaluni, Srivalli, Akce, Mehmet, Alese, Olatunji, Baron, Ari, Dunne, Richard, Loaiza-Bonilla, Arturo, Frenette, Catherine, Llovet, Josep M, Kumada, Hiromitsu, Cheng, Ann-Lii, Galle, Peter R, Kaneko, Shuichi, Wang, Anran, Mody, Kalgi, Dutcus, Corina, Dubrovsky, Leonid, Siegel, Abby B, and Finn, Richard S

Published
2023
Full Text
View/download PDF

10. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection

Author

Kodama, Kenichiro, Kawaoka, Tomokazu, Kosaka, Masanari, Johira, Yusuke, Shirane, Yuki, Miura, Ryoichi, Yano, Shigeki, Murakami, Serami, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Uchikawa, Shinsuke, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Miki, Daiki, Imamura, Michio, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, Aikata, Hiroshi, and Chayama, Kazuaki

Published
2022
Full Text
View/download PDF

11. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

Author

Kudo, Masatoshi, Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii, Vogel, Arndt, Tovoli, Francesco, Ueshima, Kazuomi, Aikata, Hiroshi, López, Carlos López, Pracht, Marc, Meng, Zhiqiang, Daniele, Bruno, Park, Joong-Won, Palmer, Daniel, Tamai, Toshiyuki, Saito, Kenichi, Dutcus, Corina E., and Lencioni, Riccardo

Published
2023
Full Text
View/download PDF

12. Useful Predictor for Exacerbation of Esophagogastric Varices after Hepatitis C Virus Eradication by Direct-Acting Antivirals

Author

Nagaoki, Yuko, primary, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Aikata, Hiroshi, additional, Hayes, C. Nelson, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2024
Full Text
View/download PDF

14. Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

Author

Naruto, Kensuke, Kawaoka, Tomokazu, Kodama, Kenichiro, Ogawa, Yutaro, Amioka, Kei, Yoshikawa, Yuki, Kikukawa, Chihiro, Suehiro, Yousuke, Yamaoka, Kenji, Ando, Yuwa, Kosaka, Yumi, Uchikawa, Shinsuke, Nakahara, Takashi, Murakami, Eisuke, Ono, Atsushi, Uchida, Takuro, Yamauchi, Masami, Okamoto, Wataru, Takahashi, Shoichi, Imamura, Michio, Chosa, Keigo, Awai, Kazuo, Kubo, Katsumaro, Nagata, Yasushi, Chayama, Kazuaki, and Aikata, Hiroshi

Published
2022
Full Text
View/download PDF

15. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

Author

Yoshikawa, Yuki, Imamura, Michio, Yamauchi, Masami, Hayes, C. Nelson, Aikata, Hiroshi, Okamoto, Wataru, Miyata, Yoshihiro, Okada, Morihito, Hattori, Noboru, Sugiyama, Kazuhiko, Yoshioka, Yukio, Toratani, Shigeaki, Takechi, Masaaki, Ichinohe, Tatsuo, Ueda, Tsutomu, Takeno, Sachio, Kobayashi, Tsuyoshi, Ohdan, Hideki, Teishima, Jun, Hide, Michihiro, Nagata, Yasushi, Kudo, Yoshiki, Iida, Koji, and Chayama, Kazuaki

Published
2022
Full Text
View/download PDF

16. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets

Author

Fujita, Masashi, Chen, Mei-Ju May, Siwak, Doris Rieko, Sasagawa, Shota, Oosawa-Tatsuguchi, Ayako, Arihiro, Koji, Ono, Atsushi, Miura, Ryoichi, Maejima, Kazuhiro, Aikata, Hiroshi, Ueno, Masaki, Hayami, Shinya, Yamaue, Hiroki, Chayama, Kazuaki, Lee, Ju-Seog, Lu, Yiling, Mills, Gordon B., Liang, Han, Nishizuka, Satoshi S., and Nakagawa, Hidewaki

Published
2022
Full Text
View/download PDF

17. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices

Author

Shirane, Yuki, Murakami, Eisuke, Imamura, Michio, Kosaka, Masanari, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Uchikawa, Shinsuke, Teraoka, Yuji, Uchida, Takuro, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Kawaoka, Tomokazu, Miki, Daiki, Yamauchi, Masami, Okamoto, Wataru, Tsuge, Masataka, Chosa, Keigo, Awai, Kazuo, Aikata, Hiroshi, and Oka, Shiro

Published
2022
Full Text
View/download PDF

18. Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma

Author

Kawamura, Ryota, Ishii, Yasutaka, Serikawa, Masahiro, Tsuboi, Tomofumi, Tsushima, Ken, Nakamura, Shinya, Hirano, Tetsuro, Ikemoto, Juri, Kiyoshita, Yusuke, Saeki, Sho, Tamura, Yosuke, Miyamoto, Sayaka, Nakamura, Kazuki, Furukawa, Masaru, Ishida, Katsunari, Arihiro, Koji, Uemura, Kenichiro, and Aikata, Hiroshi

Published
2022
Full Text
View/download PDF

19. Useful Predictor for Exacerbation of Esophagogastric Varices after Hepatitis C Virus Eradication by Direct-Acting Antivirals.

Author

Nagaoki, Yuko, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Kawaoka, Tomokazu, Miki, Daiki, Aikata, Hiroshi, Hayes, C. Nelson, Tsuge, Masataka, and Oka, Shiro

Subjects
LIVER histology, DISEASE exacerbation, RISK assessment, ESOPHAGEAL varices, RECEIVER operating characteristic curves, PLATELET count, CELIAC artery, CIRRHOSIS of the liver, BILE acids, COMPUTED tomography, DESCRIPTIVE statistics, MANN Whitney U Test, MULTIVARIATE analysis, SEVERITY of illness index, ENDOSCOPIC surgery, ANTIVIRAL agents, KAPLAN-Meier estimator, LOG-rank test, STATISTICS, HEPATITIS C, DATA analysis software, PROPORTIONAL hazards models, ENDOSCOPY, BLOOD
Abstract

To clarify the risk factors for the aggravation of esophagogastric varices (EGVs) after hepatitis C virus (HCV) eradication with direct-acting antiviral (DAA) therapy, we enrolled 167 consecutive patients with HCV-related compensated cirrhosis who achieved a sustained virological response (SVR) after DAA therapy. During a median of 69 months, EGVs were aggravated in 42 (25%) patients despite SVR. The cumulative 1-, 3-, 5-, and 10-year aggravated EGV rates were 7%, 23%, 25%, and 27%, respectively. Multivariate analysis identified a platelet count < 11.0 × 104/μL, LSM ≥ 18.0 kPa, total bile acid ≥ 33.0 μmol/L, and a diameter of left gastric vein (LGV) ≥ 5.0 mm at HCV eradication as independent risk factors for EGV aggravation post-SVR. In groups that met all of these risks, the cumulative EGV aggravation rates at 1, 3, and 5 years were 27%, 87%, and 91%, respectively. However, none of the patients who had only one or none of the risk factors experienced EGV aggravation. Platelet count, LSM, total bile acid, and diameter of LGV at HCV eradication were associated with aggravated EGV post-SVR. EGVs tend to worsen as two or more of these risk factors increase. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Correction to: Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

Author

Murakami, Serami, Imamura, Michio, Uchida, Takuro, Suehiro, Yosuke, Namba, Maiko, Fujii, Yasutoshi, Uchikawa, Shinsuke, Teraoka, Yuji, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Miki, Daiki, Hayes, Nelson C., Tsuge, Masataka, Aikata, Hiroshi, Ohira, Masahiro, Ohdan, Hideki, and Oka, Shiro

Published
2023
Full Text
View/download PDF

23. Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.

Author

Qin, Xian‐Yang, Shirakami, Yohei, Honda, Masao, Yeh, Shiou‐Hwei, Numata, Kazushi, Lai, Ya‐Yun, Li, Chiao‐Ling, Wei, Feifei, Xu, Yali, Imai, Kenji, Takai, Koji, Chuma, Makoto, Komatsu, Nagisa, Furutani, Yutaka, Gailhouste, Luc, Aikata, Hiroshi, Chayama, Kazuaki, Enomoto, Masaru, Tateishi, Ryosuke, and Kawaguchi, Kazunori

Subjects
BIOMARKERS, CLINICAL trials, PROGNOSIS, RETINOIDS, BLOOD proteins, HEPATOCELLULAR carcinoma
Abstract

The proto‐oncogene MYCN expression marked a cancer stem‐like cell population in hepatocellular carcinoma (HCC) and served as a therapeutic target of acyclic retinoid (ACR), an orally administered vitamin A derivative that has demonstrated promising efficacy and safety in reducing HCC recurrence. This study investigated the role of MYCN as a predictive biomarker for therapeutic response to ACR and prognosis of HCC. MYCN gene expression in HCC was analyzed in the Cancer Genome Atlas and a Taiwanese cohort (N = 118). Serum MYCN protein levels were assessed in healthy controls (N = 15), patients with HCC (N = 116), pre‐ and post‐surgical patients with HCC (N = 20), and a subset of patients from a phase 3 clinical trial of ACR (N = 68, NCT01640808). The results showed increased MYCN gene expression in HCC tumors, which positively correlated with HCC recurrence in non‐cirrhotic or single‐tumor patients. Serum MYCN protein levels were higher in patients with HCC, decreased after surgical resection of HCC, and were associated with liver functional reserve and fibrosis markers, as well as long‐term HCC prognosis (>4 years). Subgroup analysis of a phase 3 clinical trial of ACR identified serum MYCN as the risk factor most strongly associated with HCC recurrence. Patients with HCC with higher serum MYCN levels after a 4‐week treatment of ACR exhibited a significantly higher risk of recurrence (hazard ratio 3.27; p =.022). In conclusion, serum MYCN holds promise for biomarker‐based precision medicine for the prevention of HCC, long‐term prognosis of early‐stage HCC, and identification of high‐response subgroups for ACR‐based treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Llovet, Josep M, primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Masi, Gianluca, additional, Kwiatkowski, Mariusz, additional, Lim, Ho Yeong, additional, Kim, Jee Hyun, additional, Breder, Valeriy, additional, Kumada, Hiromitsu, additional, Cheng, Ann-Lii, additional, Galle, Peter R, additional, Kaneko, Shuichi, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dutcus, Corina, additional, Dubrovsky, Leonid, additional, Siegel, Abby B, additional, Finn, Richard S, additional, Strasser, Simone, additional, Thompson, Alexander, additional, Roohullah, Aflah, additional, Sievert, William, additional, Andelkovic, Vladimir, additional, Knox, Jennifer, additional, Davies, Janine, additional, Asselah, Jamil, additional, Brahmania, Mayur, additional, Majeed, Habeeb, additional, Villanueva, Luis, additional, Yanez Weber, Patricio, additional, Garrido, Marcelo, additional, Pizarro, Gonzalo Ignacio, additional, Yanez, Nicolas, additional, Ou, Shuangyan, additional, Pan, Hongming, additional, Meng, Zhiqiang, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Zhang, Tao, additional, Hao, Chunyi, additional, Cao, Peiguo, additional, Guo, Yabing, additional, Xiao, Juxiang, additional, Fang, Weijia, additional, Wang, Xin, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Yan, Dong, additional, Zhao, Hong, additional, Ying, Jieer, additional, Bonilla, Carlos, additional, Urrego, Olga, additional, Zambrano, Angela, additional, Lema, Mauricio, additional, Restrepo Gutierrez, Juan Carlos, additional, Cardona, Andres, additional, Franco Millan, Sandra, additional, Oscar, Madiedo, additional, Ramos, Victor, additional, LeSourd, Samuel, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Cattan, Stephane, additional, Bouattour, Mohamed, additional, Mineur, Laurent, additional, Regnault, Helene, additional, Dauvois, Barbara, additional, Schulze, Kornelius, additional, Folprecht, Gunnar, additional, Geier, Andreas, additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Venerito, Marino, additional, Berres, Marie-Luise, additional, Berg, Thomas, additional, Lange, Christian, additional, Schmidt, Hartmut, additional, Waldschmidt, Dirk T, additional, Bitzer, Michael, additional, McDermott, Ray, additional, Duffy, Austin, additional, Zagonel, Vittorina, additional, Tonini, Giuseppe, additional, Piscaglia, Fabio, additional, Gori, Stefania, additional, Rizzo, Mimma, additional, Biscaldi, Elisa, additional, Foltran, Luisa, additional, Cabibbo, Giuseppe, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Marusawa, Hiroyuki, additional, Kato, Naoya, additional, Kurosaki, Masayuki, additional, Morimoto, Manabu, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Masaki, Tsutomu, additional, Tateishi, Ryosuke, additional, Inaba, Yoshitaka, additional, Arakawa, Tomohiro, additional, Suzuki, Yoshiyuki, additional, Akua, Norio, additional, Kobayashi, Masahiro, additional, Hosaka, Tetsuya, additional, Nakamuta, Makoto, additional, Oza, Noriko, additional, Kondo, Shunsuke, additional, Furuse, Junji, additional, Nagashima, Fumio, additional, Kitano, Masayuki, additional, Takaguchi, Koichi, additional, Kim, Tae-You, additional, Kim, Han Sang, additional, Hernandez Hernandez, Carlos, additional, Motola Kuba, Daniel, additional, Segura Gonzalez, Manuel, additional, Cabrera Luviano, Jesus, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Silva-Bravo, Fernando, additional, Gane, Edward, additional, Stedman, Catherine, additional, Wyrwicz, Lucjan, additional, Nowakowska-Zajdel, Ewa, additional, Kraj, Leszek, additional, Janczewska, Ewa, additional, Surma-Wlodarczyk, Renata, additional, Sekacheva, Marina, additional, Orlova, Rashida, additional, Vasilyev, Alexander, additional, Zukov, Ruslan, additional, Vladimirov, Vladimir, additional, Minguez, Beatriz, additional, Matilla Pena, Ana, additional, Fernandez Castroagudin, Javier, additional, Romero Gomez, Manuel, additional, Luis Lledo, Jose, additional, Rubin, Angel, additional, Garcia Sanchez, Araceli, additional, Calleja Panero, Jose, additional, Yu, Ming-Chin, additional, Shen, Ying-Chun, additional, Huang, Yi-Hsiang, additional, Jeng, Long-Bin, additional, Chang, Ting-Tsung, additional, Yang, Sheng-Shun, additional, Chen, Shinn-Cherng, additional, Dechaphunkul, Arunee, additional, Tanwandee, Tawesak, additional, Leerapun, Apinya, additional, Seker, Mesut, additional, Harputluoglu, Hakan, additional, Cicin, Irfan, additional, Oksuzoglu, Berna, additional, Bilici, Mehmet, additional, Sezgin Goksu, Sema, additional, Artac, Mehmet, additional, Cil, Timucin, additional, Yalcin, Suayib, additional, Sarker, Debashis, additional, Rao, Ankit, additional, Palmer, Daniel, additional, Evans, Jeff, additional, Hubner, Richard, additional, Finn, Richard, additional, Ulahannan, Susanna, additional, Zakari, Ahmed, additional, Feun, Lynn, additional, Al-Rajabi, Raed, additional, Sung, Max, additional, He, Aiwu, additional, Kardosh, Adel, additional, Goyal, Lipika, additional, Li, Daneng, additional, Choi, Minsig, additional, Posada, Juan, additional, Dodlapati, Jyothi, additional, Shroff, Rachna, additional, Agrawal, Saurabh, additional, Gopaluni, Srivalli, additional, Akce, Mehmet, additional, Alese, Olatunji, additional, Baron, Ari, additional, Dunne, Richard, additional, Loaiza-Bonilla, Arturo, additional, and Frenette, Catherine, additional

Published
2023
Full Text
View/download PDF

29. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication

Author

Miki, Daiki, Akita, Tomoyuki, Kurisu, Akemi, Kawaoka, Tomokazu, Nakajima, Tomoaki, Hige, Shuhei, Karino, Yoshiyasu, Toyoda, Hidenori, Kumada, Takashi, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Aikata, Hiroshi, Hayes, Clair Nelson, Honda, Koichi, Seike, Masataka, Akuta, Norio, Kobayashi, Mariko, Kumada, Hiromitsu, Tanaka, Junko, and Chayama, Kazuaki

Published
2020
Full Text
View/download PDF

32. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study

Author

Nagaoki, Yuko, Hyogo, Hideyuki, Ando, Yuwa, Kosaka, Yumi, Uchikawa, Shinsuke, Nishida, Yuno, Teraoka, Yuji, Morio, Kei, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Yamauchi, Masami, Okamoto, Wataru, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Miki, Daiki, Imamura, Michio, Takahashi, Shoichi, Chayama, Kazuaki, and Aikata, Hiroshi

Published
2021
Full Text
View/download PDF

34. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture

Author

Álvarez, Eva G., Demeulemeester, Jonas, Otero, Paula, Jolly, Clemency, García-Souto, Daniel, Pequeño-Valtierra, Ana, Zamora, Jorge, Tojo, Marta, Temes, Javier, Baez-Ortega, Adrian, Rodriguez-Martin, Bernardo, Oitaben, Ana, Bruzos, Alicia L., Martínez-Fernández, Mónica, Haase, Kerstin, Zumalave, Sonia, Abal, Rosanna, Rodríguez-Castro, Jorge, Rodriguez-Casanova, Aitor, Diaz-Lagares, Angel, Li, Yilong, Raine, Keiran M., Butler, Adam P., Otero, Iago, Ono, Atsushi, Aikata, Hiroshi, Chayama, Kazuaki, Ueno, Masaki, Hayami, Shinya, Yamaue, Hiroki, Maejima, Kazuhiro, Blanco, Miguel G., Forns, Xavier, Rivas, Carmen, Ruiz-Bañobre, Juan, Pérez-del-Pulgar, Sofía, Torres-Ruiz, Raúl, Rodriguez-Perales, Sandra, Garaigorta, Urtzi, Campbell, Peter J., Nakagawa, Hidewaki, Van Loo, Peter, and Tubio, Jose M. C.

Published
2021
Full Text
View/download PDF

35. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

Author

Cheng, Xiaoming, Uchida, Takuro, Xia, Yuchen, Umarova, Regina, Liu, Chun-Jen, Chen, Pei-Jer, Gaggar, Anuj, Suri, Vithika, Mucke, Marcus M., Vermehren, Johannes, Zeuzem, Stefan, Teraoka, Yuji, Osawa, Mitsutaka, Aikata, Hiroshi, Tsuji, Keiji, Mori, Nami, Hige, Shuhei, Karino, Yoshiyasu, Imamura, Michio, Chayama, Kazuaki, and Liang, T. Jake

Subjects
United States. Food and Drug Administration, Sofosbuvir -- Health aspects, Backup software -- Health aspects, Biological response modifiers -- Health aspects, Medical research -- Health aspects, Infection -- Health aspects, Hepatitis C virus -- Health aspects, Interferon -- Health aspects, Comorbidity -- Health aspects, Hepatitis B -- Health aspects, Backup software, Health care industry
Abstract

In patients with HBV and HCV coinfection, HBV reactivation leading to severe hepatitis has been reported with the use of direct-acting antivirals (DAAs) to treat HCV infection. Here we studied the molecular mechanisms behind this viral interaction. In coinfected cell culture and humanized mice, HBV replication was suppressed by HCV coinfection. In vitro, HBV suppression was attenuated when interferon (IFN) signaling was blocked. In vivo, HBV viremia, after initial suppression by HCV superinfection, rebounded following HCV clearance by DAA treatment that was accompanied by a reduced hepatic IFN response. Using blood samples of coinfected patients, IFN-stimulated gene products including C-X-C motif chemokine 10 (CXCL10), C-C motif chemokine ligand 5 (CCL5), and alanine aminotransferase (ALT) were identified to have predictive value for HBV reactivation after HCV clearance. Taken together, our data suggest that HBV reactivation is a result of diminished hepatic IFN response following HCV clearance and identify serologic markers that can predict HBV reactivation in DAA-treated HBV-HCV-coinfected persons., Introduction Hepatitis B virus (HBV) and hepatitis C virus (HCV) together infect more than 300 million people worldwide. Due to the shared modes of transmission and epidemiological features, they frequently [...]

Published
2020
Full Text
View/download PDF

37. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk

Author

Kosaka, Yumi, Kawaoka, Tomokazu, Aikata, Hiroshi, Suehiro, Yosuke, Yamaoka, Kenji, Ando, Yuwa, Namba, Maiko, Takeuchi, Yasue, Fujii, Yasutomo, Uchikawa, Shinsuke, Kodama, Kenichiro, Oya, Kazuki, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Yamauchi, Masami, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Baba, Yasutaka, Awai, Kazuo, Kimura, Tomoki, Nagata, Yasushi, and Chayama, Kazuaki

Published
2020
Full Text
View/download PDF

41. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy

Author

Ohya, Kazuki, Imamura, Michio, Osawa, Mitsutaka, Teraoka, Yuji, Morio, Kei, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Yamauchi, Masami, Kawaoka, Tomokazu, Hiramatsu, Akira, Tsuge, Masataka, Aikata, Hiroshi, Hayes, Clair Nelson, and Chayama, Kazuaki

Published
2020
Full Text
View/download PDF

44. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Author

Yamashita, Tatsuya, Kudo, Masatoshi, Ikeda, Kenji, Izumi, Namiki, Tateishi, Ryosuke, Ikeda, Masafumi, Aikata, Hiroshi, Kawaguchi, Yasunori, Wada, Yoshiyuki, Numata, Kazushi, Inaba, Yoshitaka, Kuromatsu, Ryoko, Kobayashi, Masahiro, Okusaka, Takuji, Tamai, Toshiyuki, Kitamura, Chifumi, Saito, Kenichi, Haruna, Katsuya, Okita, Kiwamu, and Kumada, Hiromitsu

Published
2020
Full Text
View/download PDF

45. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD.

Author

Ikeda, Masafumi, Yamashita, Tatsuya, Ogasawara, Sadahisa, Kudo, Masatoshi, Inaba, Yoshitaka, Morimoto, Manabu, Tsuchiya, Kaoru, Shimizu, Satoshi, Kojima, Yasushi, Hiraoka, Atsushi, Nouso, Kazuhiro, Aikata, Hiroshi, Numata, Kazushi, Sato, Tosiya, Okusaka, Takuji, and Furuse, Junji

Subjects
INTRA-arterial infusions, CISPLATIN, HEPATOCELLULAR carcinoma, CLINICAL trials, OVERALL survival
Abstract

Introduction: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher antitumor activity is expected for the combination treatment. The aim of this trial was to evaluate the efficacy and safety of lenvatinib in combination with HAIC using cisplatin in patients with advanced HCC. Methods: In this multicenter, open-labeled, single-arm, phase II trial, patients with advanced HCC categorized as Child-Pugh class A with no prior history of systemic therapy were enrolled. Patients received lenvatinib plus HAIC with cisplatin (lenvatinib: 12 mg once daily for patients ≥60 kg, 8 mg once daily for patients <60 kg; HAIC with cisplatin: 65 mg/m2, day 1, every 4–6 weeks, maximum of six cycles). The primary endpoint was the objective response rate (ORR) assessed using modified RECIST by the Independent Review Committee. The secondary endpoints were the ORR assessed using RECIST v1.1, progression-free survival, overall survival, and frequency of adverse events associated with the treatment. Results: A total of 36 patients were enrolled between September 2018 and March 2020. In the 34 evaluable patients, the ORR assessed by the Independent Review Committee using modified RECIST and RECIST v1.1 were 64.7% (95% confidence interval [CI]: 46.5–80.3%) and 45.7% (95% CI: 28.8–63.4%), respectively. The median progression-free survival and overall survival were 6.3 months (95% CI: 5.1–7.9 months) and 17.2 months (95% CI: 10.9 – not available, months), respectively. The main grade 3–4 adverse events were increased aspartate aminotransferase (34%), leukopenia (22%), increased alanine aminotransferase (19%), and hypertension (11%). Conclusion: Lenvatinib plus HAIC with cisplatin yielded a favorable ORR and overall survival and was well tolerated in patients with advanced HCC. Further evaluation of this regimen in a phase III trial is warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab

Author

Yano, Shigeki, Kawaoka, Tomokazu, Johira, Yusuke, Miura, Ryoichi, Kosaka, Masanari, Shirane, Yuki, Murakami, Serami, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Yamaoka, Kenji, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ohno, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Imamura, Michio, Mori, Keiichi, Arihiro, Kouji, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, and Aikata, Hiroshi

Published
2021
Full Text
View/download PDF

47. Outcomes and Prognostic Analysis of Surgical Resection for Oligometastasis from Hepatocellular Carcinoma

Author

OSHITA, KO, primary, KOBAYASHI, TSUYOSHI, additional, TADOKORO, TAKESHI, additional, NAMBA, YOSUKE, additional, FUKUHARA, SOTARO, additional, MATSUBARA, KEISO, additional, TAKEI, DAISUKE, additional, HONMYO, NARUHIKO, additional, KURODA, SHINTARO, additional, KAWAOKA, TOMOKAZU, additional, AIKATA, HIROSHI, additional, and OHDAN, HIDEKI, additional

Published
2023
Full Text
View/download PDF

48. Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study

Author

Oshita, Ko, primary, Kobayashi, Tsuyoshi, additional, Namba, Yosuke, additional, Fukuhara, Sotaro, additional, Matsubara, Keiso, additional, Takei, Daisuke, additional, Nakano, Ryosuke, additional, Okamoto, Wataru, additional, Sakai, Hiroshi, additional, Tanimine, Naoki, additional, Nakahara, Takashi, additional, Kuroda, Shintaro, additional, Tahara, Hiroyuki, additional, Ohira, Masahiro, additional, Kawaoka, Tomokazu, additional, Ide, Kentaro, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Ohdan, Hideki, additional

Published
2023
Full Text
View/download PDF

49. Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab

Author

Kikugawa, Chihiro, primary, Uchikawa, Shinsuke, additional, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Tsuge, Masataka, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yohji, additional, Naeshiro, Noriaki, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results